Product logins

Find logins to all Clarivate products below.


Last Updated 8 December 2015
The hepatitis C virus (HCV) therapy market is undergoing unprecedented growth. Commercial opportunity is driven by a large prevalent population and historically high unmet medical need due to the suboptimal efficacy and tolerability of interferon-based therapies. Between 2013 and 2015, several direct-acting antivirals (DAAs) and DAA combinations, including simeprevir (Janssen’s Olysio, Medivir’s Sovriad), sofosbuvir (Gilead’s Sovaldi), sofosbuvir/ledipasvir (Gilead’s Harvoni), ombitasvir/paritaprevir/ritonavir plus dasabuvir (AbbVie’s Viekira Pak), and daclatasvir (Bristol-Myers Squibb’s Daklinza), have launched in the G7 for both treatment-naive and -experienced HCV patients. Despite these agents’ high prices, they have become a new standard of care.

Related Market Assessment Reports

Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…